Sandbox:Amd: Difference between revisions
Jump to navigation
Jump to search
Line 15: | Line 15: | ||
! rowspan="3" style="background:#4479BA; color: #FFFFFF;" |Etiology | ! rowspan="3" style="background:#4479BA; color: #FFFFFF;" |Etiology | ||
! colspan="7" style="background:#4479BA; color: #FFFFFF;" |Clinical manifestations | ! colspan="7" style="background:#4479BA; color: #FFFFFF;" |Clinical manifestations | ||
! colspan=" | ! colspan="5" style="background:#4479BA; color: #FFFFFF;" |Paraclinical findings | ||
! rowspan="3" style="background:#4479BA; color: #FFFFFF;" |Comments | ! rowspan="3" style="background:#4479BA; color: #FFFFFF;" |Comments | ||
|- | |- | ||
! colspan="7" style="background:#4479BA; color: #FFFFFF;" |Symptoms and signs | ! colspan="7" style="background:#4479BA; color: #FFFFFF;" |Symptoms and signs | ||
! colspan=" | ! colspan="5" style="background:#4479BA; color: #FFFFFF;" |Lab findings/Urine exam | ||
|- | |- | ||
| align="center" style="background:#4479BA; color: #FFFFFF;" |Dysuria | | align="center" style="background:#4479BA; color: #FFFFFF;" |Dysuria | ||
Line 29: | Line 29: | ||
| align="center" style="background:#4479BA; color: #FFFFFF;" |Others | | align="center" style="background:#4479BA; color: #FFFFFF;" |Others | ||
| align="center" style="background:#4479BA; color: #FFFFFF;" |Serum osmolarity | | align="center" style="background:#4479BA; color: #FFFFFF;" |Serum osmolarity | ||
| align="center" style="background:#4479BA; color: #FFFFFF;" |S. ADH | | align="center" style="background:#4479BA; color: #FFFFFF;" |S. ADH | ||
| align="center" style="background:#4479BA; color: #FFFFFF;" |Urine osmolarity | | align="center" style="background:#4479BA; color: #FFFFFF;" |Urine osmolarity | ||
Line 44: | Line 43: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |– | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |– | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Increased thirst | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |Increased thirst | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal | ||
Line 52: | Line 50: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
|- | |- | ||
! rowspan=" | ! rowspan="3" style="padding: 5px 5px; background: #DCDCDC;" align="center" |Increased solute excretion | ||
! | ! style="padding: 5px 5px; background: #DCDCDC;" align="center" |Osmotic causes | ||
| style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Diabetes mellitus]] | | style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Diabetes mellitus]]<ref name="pmid104991902">{{cite journal| author=Ahloulay M, Schmitt F, Déchaux M, Bankir L| title=Vasopressin and urinary concentrating activity in diabetes mellitus. | journal=Diabetes Metab | year= 1999 | volume= 25 | issue= 3 | pages= 213-22 | pmid=10499190 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10499190 }}</ref> | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |– | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |– | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |± | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |± | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |– | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |– | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |– | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |Late stage | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Hyperosmolar hyperglycemic state]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |High in Type 2 | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |No effect | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |No effect | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
|- | |- | ||
! rowspan="2" style="padding: 5px 5px; background: #DCDCDC;" align="center" |Salt loss | ! rowspan="2" style="padding: 5px 5px; background: #DCDCDC;" align="center" |Salt loss | ||
| style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Diuretics]] | | style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Diuretics]] | ||
| | |– | ||
| | | + | ||
| | |– | ||
| | | + | ||
| | |– | ||
| | | | ||
| | | | ||
Line 104: | Line 84: | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Cerebral salt-wasting syndrome]] | | style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Cerebral salt-wasting syndrome]] | ||
| | | | ||
| | | | ||
Line 122: | Line 101: | ||
! rowspan="2" style="padding: 5px 5px; background: #DCDCDC;" align="center" |Low ADH | ! rowspan="2" style="padding: 5px 5px; background: #DCDCDC;" align="center" |Low ADH | ||
| style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Central diabetes insipidus]] | | style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Central diabetes insipidus]] | ||
| | | | ||
| | | | ||
Line 138: | Line 116: | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Nephrogenic diabetes insipidus]] | | style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Nephrogenic diabetes insipidus]] | ||
| | | | ||
| | | | ||
Line 155: | Line 132: | ||
! rowspan="2" style="padding: 5px 5px; background: #DCDCDC;" align="center" |Renal disease | ! rowspan="2" style="padding: 5px 5px; background: #DCDCDC;" align="center" |Renal disease | ||
| style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Renal tubular acidosis]] | | style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Renal tubular acidosis]] | ||
| | | | ||
| | | | ||
Line 171: | Line 147: | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Bartter syndrome]] | | style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Bartter syndrome]] | ||
| | | | ||
| | | |
Revision as of 02:18, 11 May 2018
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Amandeep Singh M.D.[2]
Differential diagnosis
Abbreviations: Na= Natrium/ Sodium, ADH= Antidiuretic hormone
POLYURIA
Mechanism | Etiology | Clinical manifestations | Paraclinical findings | Comments | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Symptoms and signs | Lab findings/Urine exam | ||||||||||||||
Dysuria | Nocturia | Hesitancy | Dribbling | Hematuria | Proteinuria | Others | Serum osmolarity | S. ADH | Urine osmolarity | Water deprivation test | ADH administration | ||||
Increased intake of fluid | Psychogenic polydipsia[1] | – | – | – | – | – | – | Increased thirst | Normal | Normal | Low | Improves urine osmolarity | No improvement | ||
Increased solute excretion | Osmotic causes | Diabetes mellitus[2] | – | ± | – | – | – | Late stage | Hyperosmolar hyperglycemic state | High in Type 2 | Normal | Normal | No effect | No effect | |
Salt loss | Diuretics | – | + | – | + | – | |||||||||
Cerebral salt-wasting syndrome | |||||||||||||||
Impaired urinary concentration | Low ADH | Central diabetes insipidus | |||||||||||||
Nephrogenic diabetes insipidus | |||||||||||||||
Renal disease | Renal tubular acidosis | ||||||||||||||
Bartter syndrome |
Differential diagnosis
Abbreviations: AP= Anteroposterior, CXR= Chest X-ray, CT= Computed tomography, ABG= Arterial blood gas, V/Q= Ventilation/perfusion scan , EKG= Electrocardiogram, COPD= Chronic obstructive pulmonary disease, BNP= Brain natriuretic peptide, DVT= Deep vein thrombosis, HRCT= High Resolution CT, IgE= Immunoglobulin E
|
References
- ↑ Mellinger RC, Zafar MS (1983). "Primary polydipsia. Syndrome of inappropriate thirst". Arch Intern Med. 143 (6): 1249–51. PMID 6860053.
- ↑ Ahloulay M, Schmitt F, Déchaux M, Bankir L (1999). "Vasopressin and urinary concentrating activity in diabetes mellitus". Diabetes Metab. 25 (3): 213–22. PMID 10499190.
- ↑ Cherry, James D. (2008). "Croup". New England Journal of Medicine. 358 (4): 384–391. doi:10.1056/NEJMcp072022. ISSN 0028-4793.
- ↑ Khurshid I, Downie GH (2002). "Pulmonary arteriovenous malformation". Postgrad Med J. 78 (918): 191–7. PMC 1742331. PMID 11930021.
- ↑ Doshi HM, Robinson S, Chalhoub T, Jack S, Denison A, Gibson G (2009). "Massive spontaneous hemothorax during the immediate postpartum period". Tex Heart Inst J. 36 (3): 247–9. PMC 2696501. PMID 19568398.
- ↑ Chanatry BJ (1992). "Acute hemothorax owing to pulmonary arteriovenous malformation in pregnancy". Anesth. Analg. 74 (4): 613–5. PMID 1554132.